Editorial Policies

Focus and Scope

The Chemical Biology Letter provides a forum for publication of quality original research at the interface of chemistry and biology. Chemical biology letters covers the scientific ideas and approaches of chemistry, biology and allied interdisciplinary areas such as medicinal chemistry, drug discovery, drug delivery, biosensor, protein chemistry, biological chemistry, biomolecules, bio-technology, biomedical, molecular biology and other allied areas covering chemistry and biology for the better understanding of biological phenomenon at molecular level. The journal accepts research articles from the community of chemical biologists.


Section Policies

Research Articles

Regular Research Article

Unchecked Open Submissions Checked Indexed Checked Peer Reviewed

Review Article

Review article related to chemistry biology interface.

Unchecked Open Submissions Checked Indexed Checked Peer Reviewed

Short Communications

Short Communications/Letters from Chemical Biology.

Unchecked Open Submissions Checked Indexed Checked Peer Reviewed

Nuclear Medicine - Special Issue

The section is meant for articles (research, review and short communications) for special issue on Nuclear Medicine.

Unchecked Open Submissions Checked Indexed Checked Peer Reviewed

Peer Review Process

The journal uses ‘Single Blind Review’ of the manuscripts: Reviewer may see the author details, while identity of reviewers is not disclosed to authors. The reviewers must maintain the confidentiality during reviewing and post review of manuscript. The manuscript work should be evaluated in respective field of expertise and detailed feedback and recommendation should be provided to editors.


On average, submitted manuscripts would be reviewed by three independent reviewers.


About CBL

The Chemical Biology Letters is a top-tier venue for discoveries at the interface of chemistry and biology, chemical biology, synthetic biology, and in basic and applied biomedical research covering recent advances in drugs and therapeutics development. The CBL:

  • would provide all contents on online site for wide circulation and get contents indexed in different scientific content databases.
  • provides free access to all of its research articles for one or more months for each issue,
  • would deposit published research articles in different databases and would satisfy the NIH Public Access Policy guidlines. 
  • is an ideal home for authors seeking the broadest audience for their most important work.

The journal is led by Editors and supported by Editorial Advisory Board of peer scientists from various reputed universities, research institutes and other reputed Medical Research Institutes whose depth and experience ensure fair and competent peer review.

Sending your work to the CBL

The journal considers research submissions in several categories. The CBL receives submissions only through its website; submissions by mail or e-mail will be returned. 

Do you have a question about a manuscript you've already submitted?

  • When a manuscript is received and confirmed by the CBL, an acknowledgment is sent via e-mail to the corresponding author. For any communication with us, please reference the tracking number assigned by the CBL noted in the acknowledgment. 
  • In order to avoid confusion regarding correspondence, inquiries, and decisions, the CBL will typically communicate only with those who are designated as corresponding authors during the submission process.


Manuscript submitted and processed for reviewing can't be withdrawn. If authors donot respond to emails for the reviewed and accepted manuscript, then the article will be published by the journal in as such format with a note 'withdrawn by authors' by no response.


See more details on the Journal new site: https://pubs.thesciencein.org/journal/index.php/cbl/about/